Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

AZD1390 Demonstrates Initial Safety, May Enhance Radiotherapy Efficacy in Glioblastoma

April 9th 2024

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

VBI-1901 Elicits Disease Control in Recurrent Glioblastoma

April 3rd 2024

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

Raising Hope

March 18th 2024

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Novel CAR T-Cell Therapy Displays Activity in Glioblastoma

March 18th 2024

Treatment with a next-generation CAR T-cell agent displayed early efficacy in a small group of patients with glioblastoma.

Dual-Targeted CAR T-Cell Therapy Displays Early Efficacy in Recurrent Glioblastoma

March 13th 2024

A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.

FDA and EMA Accept Regulatory Submissions for Vorasidenib for IDH-Mutant Diffuse Glioma

February 20th 2024

Vorasidenib has been granted regulatory submission acceptance by the FDA and EMA for IDH-mutant diffuse glioma.

FDA Grants Fast Track Designation to CAN-3110 for Recurrent High-Grade Glioma

February 13th 2024

CAN-3110, an HSV-1 oncolytic viral immunotherapy candidate, has received FDA fast track designation for adult patients with recurrent high-grade glioma.

NCCN Releases First Neuroblastoma Treatment Recommendations

February 12th 2024

The NCCN has published the first set of treatment recommendations for neuroblastoma.

Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas

January 24th 2024

Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.

Dr Sumrall on the Clinical Efficacy of ONC201 in H3K27M -Mutant Diffuse Midline Gliomas

January 8th 2024

Ashley Sumrall, MD, FACP, medical oncologist, section chief, Neuro-Oncology, clinical assistant professor, medicine, Atrium Health, Levine Cancer Institute, discusses the clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas.

EO2401 Plus Nivolumab and Bevacizumab Shows Activity in Progressive/Recurrent Glioblastoma

November 20th 2023

The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.

FDA Grants Fast Track Designation to RZ-001 for Glioblastoma

November 15th 2023

The FDA has granted fast track designation to the RNA replacement enzyme–based cancer gene therapy RZ-001 for the treatment of patients with glioblastoma, according to an announcement from Rznomics Inc.

FG001 Meets Detection End Point in High-Grade Glioma

November 14th 2023

The use of the optical imaging agent FG001 led to the detection of additional cancer by optical guidance in patients with high-grade glioma, meeting the primary end point of the phase 2b FG001-CT-001 trial.

VAL-083 Fails to Outperform SOC in Glioblastoma

October 31st 2023

VAL-083 did not improve efficacy compared with standard-of-care approaches in patients with glioblastoma.

FDA Grants Priority Review to Tovorafenib in Pediatric Relapsed/Progressive Low-Grade Glioma

October 30th 2023

The FDA has granted priority review to a new drug application seeking the approval of tovorafenib monotherapy for the treatment of pediatric patients with relapsed or progressive low-grade glioma.

FDA Grants Orphan Drug Designation to TTX101 in Malignant Glioma

October 25th 2023

The FDA has granted an orphan drug designation to TTX101 as a potential therapeutic option for patients with malignant glioma.

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17th 2023

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

FDA Grants Fast Track Designation to SurVaxM in Newly Diagnosed Glioblastoma

October 12th 2023

The FDA has granted fast track designation to the investigational vaccine SurVaxM for the treatment of patients with newly diagnosed glioblastoma.

FDA Panel Votes Sufficient Evidence Available to Support EFS Benefit of Eflornithine in Pediatric High-Risk Neuroblastoma

October 6th 2023

In a 14-to-6 vote, the FDA’s Oncologic Drugs Advisory Committee voted sufficient evidence has been provided to demonstrate the event-free survival benefit of eflornithine to reduce the risk of relapse in pediatric patients with high-risk neuroblastoma.

FDA Awards Orphan Drug Designation to FG001 in High-Grade Glioma

October 4th 2023

The FDA has granted an orphan drug designation to FG001 as an optical imaging agent for the visualization of malignant tissue during surgery for patients with high-grade glioma.